Lupin Strengthens US Portfolio with FDA Approval and 180-Day Market Exclusivity

$LUPIN has received approval from the U.S. Food and Drug Administration (US FDA) for its generic version of Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets in the strengths of 1.479 g/0.225 g/0.188 g, a product used for colon cleansing before colonoscopy procedures in adults. The company stated that the product is bioequivalent to Sutab, the reference drug marketed by Azurity Pharmaceuticals. A key highlight of the approval is that Lupin is the exclusive first-to-file applicant, making it eligible for 180 days of generic drug exclusivity in the U.S. market, which can provide a significant competitive advantage. The product will be manufactured at Lupin’s Nagpur facility in India. According to industry estimates, the reference drug generated annual U.S. sales of approximately $132.8 million as of March 2026. The approval further strengthens Lupin’s presence in the U.S. generics market, where the company expects its business to remain above the $1 billion mark in FY27, supported by products such as Tolvaptan, Mirabegron, recent injectable launches, and future contributions from biosimilars and specialty medicines. The development reflects Lupin’s continued focus on expanding its regulated market portfolio and enhancing long-term growth opportunities. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.